Topic Hub
7 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 7 of 7 clinical reviews.
A deep methodological critique of the SELECT trial (semaglutide 2.4 mg, NEJM 2023): enrollment biases, follow-up gaps, statistical caveats, COI concerns, and what post-publication commentary revealed.
Read clinical reviewA deep-dive into the SELECT trial's randomization, blinding, endpoint adjudication, estimand framework, and statistical design that shaped the landmark 20% MACE reduction with semaglutide 2.4 mg.
Read clinical reviewA deep-dive into the health-economic evidence from the SELECT trial: cost-per-QALY estimates, payer-coverage dynamics, list-price vs net-price reality, and how individual patients can weigh the relative value of semaglutide 2.4 mg for cardiovascular risk reduction.
Read clinical reviewWhat the SELECT trial's follow-up and extension analyses reveal about the durability of semaglutide 2.4 mg's cardiovascular benefits, long-term safety signals, and unanswered questions beyond the primary endpoint.
Read clinical reviewA deep-dive into the SELECT trial's primary and secondary endpoint results for semaglutide 2.4 mg, including effect sizes, confidence intervals, subgroup analyses, and the time-course pattern of cardiovascular benefit.
Read clinical reviewDeep dive into the SELECT trial's pre-specified and post-hoc subgroup analyses for semaglutide 2.4 mg, examining differential MACE reduction by age, sex, BMI, race, and baseline biomarkers in patients with overweight/obesity and established cardiovascular disease.
Read clinical reviewHow the SELECT trial's 20% MACE reduction with semaglutide 2.4 mg reshapes prescribing for patients with obesity and established cardiovascular disease, even without diabetes.
Read clinical review